An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)

Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib Treatment in Patients With Metastatic Colorectal Cancer

NCT07124858 ·Status: NOT_YET_RECRUITING ·Phase: NA

High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28

NCT03329183 ·Status: UNKNOWN ·Phase: PHASE2

Biomarker Directed Treatment in Metastatic Colorectal Cancer

NCT01703390 ·Status: COMPLETED ·Phase: PHASE2

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

NCT02605044 ·Status: TERMINATED ·Phase: PHASE3

ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line

NCT02624895 ·Status: COMPLETED

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

NCT06148402 ·Status: RECRUITING ·Phase: PHASE2

High Dose Simplified Folfiri in Advanced Colorectal Cancer: a Multicentre Phase II Study

NCT00286000 ·Status: COMPLETED ·Phase: PHASE2

A Prospective, Open-label, Single-arm Phase II Clinical Study of Fruquintinib Combined With S-1 for the Treatment of Metastatic Colorectal Cancer.

NCT06746545 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

An Observational Study to Evaluate the Safety and Efficacy of FOLFIRI / FOLFOX Plus Cetuximab as First-line Therapy in Patients With KRAS Wild-type Metastatic Colorectal Cancer

NCT01134666 ·Status: TERMINATED

Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC

NCT02948985 ·Status: UNKNOWN

Retrospective Evaluation of 5-FU Exposure Optimization in CRC Patients

NCT02055560 ·Status: COMPLETED

Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer

NCT05004441 ·Status: UNKNOWN ·Phase: PHASE2

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

NCT00967616 ·Status: COMPLETED ·Phase: PHASE2

TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC

NCT03517618 ·Status: COMPLETED ·Phase: PHASE2

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

NCT03035253 ·Status: TERMINATED ·Phase: PHASE1

A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM

NCT03493061 ·Status: COMPLETED ·Phase: PHASE2

Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC

NCT03222089 ·Status: WITHDRAWN ·Phase: PHASE2

Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone

NCT00890305 ·Status: COMPLETED ·Phase: PHASE2

Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan

NCT00507143 ·Status: UNKNOWN ·Phase: NA

Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer

NCT03487939 ·Status: UNKNOWN ·Phase: PHASE2

Real World Study of Regorafenib Versus Fruquintinib in Colorectal Cancer

NCT04431791 ·Status: UNKNOWN

Fruquintinib as a Maintenance Therapy Following First-line Treatment for Metastatic Colorectal Cancer

NCT04296019 ·Status: UNKNOWN ·Phase: PHASE2

A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer

NCT01326000 ·Status: COMPLETED ·Phase: PHASE2

A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer

NCT01189942 ·Status: COMPLETED ·Phase: PHASE1

FOLFOXIRI Compared With FOLFIRI for Metastatic Colorectal Cancer

NCT01219920 ·Status: COMPLETED ·Phase: PHASE3